Skip to main content

Table 1 Clinical characteristics of the study population at baseline

From: Skin autofluorescence predicts new cardiovascular disease and mortality in people with type 2 diabetes

Characteristic

New T2D

Known T2D

P-value

Sex (n; male/female)

569/462

656/662

0.009

Age (years)

55.0 ± 12.0

58.7 ± 10.8

< 0.001

BMI (kg/m2)

29.9 ± 5.2

30.5 ± 5.5

0.009

Waist (cm)

103 ± 13

104 ± 14

0.009

Systolic BP (mmHg)

136 ± 17

135 ± 17

0.103

Diastolic BP (mmHg)

78 ± 10

75 ± 9

< 0.001

Heart rate (bpm)

73 ± 12

74 ± 12

0.827

Creatinine (μmol/l)

75 ± 16

74 ± 17

0.052

eGFR (ml/min/1.73m2)

90 ± 16

88 ± 17

0.003

Total cholesterol (mmol/l)

5.3 ± 1.2

4.5 ± 1.0

< 0.001

HDL-cholesterol (mmol/l)

1.26 ± 0.36

1.27 ± 0.36

0.433

LDL-cholesterol (mmol/l)

3.4 ± 1.0

2.7 ± 0.9

< 0.001

Triacylglycerol (mmol/l)

1.88 ± 1.30

1.70 ± 1.11

< 0.001

Glucose (mmol/l)

7.6 ± 2.3

7.6 ± 2.1

0.747

HbA1c (mmol/mol)

49 ± 14

52 ± 11

< 0.001

HbA1c (%)

6.7 ± 1.2

6.9 ± 1.0

< 0.001

Current smoking (%)

23.7

14.4

< 0.001

Former smoking (%)

42.5

51.1

< 0.001

% w. BP-lowering therapy

35.7

63.4

< 0.001

% w. statins

20.1

63.0

< 0.001

Skin autofluorescence (AU)

2.25 ± 0.50

2.42 ± 0.54

< 0.001

SAF z score

0.34 ± 0.89

0.56 ± 0.99

< 0.001

  1. Data are presented as mean ± SD, number or %